NMDP BioTherapies℠ (formerly known as the Be The Match BioTherapies), a leader in cell and gene therapy development support, announced it is relaunching an improved suite of premium services for developers of autologous cell and gene therapies in response to demand from its customer base of allogeneic services.
“Our customers have continued to tell us that the regulatory, industry and operational complexities inherent in autologous sourcing and delivery are onerous – especially in a relatively nascent cell and gene therapy industry,” Tom Hochuli, CEO and President of NMDP BioTherapies, said. “We reimagined a premium level of end-to-end support, to continually improve how we advance comprehensive autologous cell therapy development support that serves our customers’ patient needs.”
Next Generation Advancements in Autologous Cell Therapy Development
These best-in-class offerings are designed to ensure consistency in the collection, packaging and shipping of critical autologous starting materials and manufactured biotech products. This slate of premium services support NMDP BioTherapies’ apheresis network and managed logistics services, including apheresis center (AC) qualification and onboarding, apheresis network management, as well as 24/7/365 logistics and supply chain support, featuring client-specific dedicated teams. NMDP BioTherapies has onboarded, trained, or managed over 165 ACs globally for clients developing autologous cell and gene therapies and has brought to bear its expertise in handling global logistics for autologous developers since its inception in 2016.
Also Read: Real Chemistry and Corval Join Forces in Biopharma
“Our suite of services balances two critical – and sometimes – opposing forces,” said Jeni Newman, senior director of operations at NMDP BioTherapies. “Providing premier apheresis network support and managed logistics services is critical to cell and gene developers as well as patients in need, but those services need to be delivered in a way that minimizes cost.”
NMDP BioTherapies has supported organizations creating next-generation autologous cell and gene therapies since 2016, leveraging NMDP’s experience building and managing a national apheresis network and orchestrating time sensitive delivery of over 130,000 life-saving cell therapies over the past 35 years. With this expertise, NMDP BioTherapies is uniquely able to help its clients overcome challenges scaling collection networks and managing complex logistics to deliver ever-increasing volumes of autologous cell and gene therapies safely, reliably, and cost effectively.
Additionally, as part of the reintroduction of these services to cell therapy developers, members of the NMDP BioTherapies team will be attending the 2024 Cell & Gene Meeting on the Mesa, which is taking place from October 7 to 9 in Phoenix, AZ.
SOURCE: Businesswire